Aier Eye Hospital

Aier Eye Hospital, also known as Aier or Aier Eye Care, is a private ophthalmology healthcare group headquartered in Changsha, Hunan. Founded in 2003 by Chen Bang, the group opened its first hospital in Changsha and developed a chain-based model focused on specialist eye care. Its services span diagnosis, surgery, treatment and follow-up for conditions such as cataracts and glaucoma, together with refractive and myopia-related procedures and other vision-correction services. Aier’s expansion was supported in part by institutional financing. In 2006, the International Finance Corporation provided a CNY 64 million loan intended to support expansion and improve access to eye care. In 2009, the related operating company completed an initial public offering on the Shenzhen Stock Exchange under ticker 300015.SZ. The listing was described in the reference material as the first public listing by a medical institution in China, giving Aier access to capital for continued network development. The group has also invested in medical education and professional training. In 2013 it established the Aier School of Ophthalmology at Central South University, described as China’s first specialized ophthalmic college, and established a College of Optometry with Hubei University of Science and Technology. These institutions support the group’s wider emphasis on clinical expertise, optometry and the development of ophthalmology personnel. Aier has used acquisitions and investments to extend beyond mainland China. It acquired Hong Kong Asia Medical Group in 2015, entered Spain through the 2017 acquisition of Clinica Baviera, and also acquired an eye clinic in the United States during 2017. In Singapore, it acquired an initial 35% interest in SEC Healthcare in 2019 and subsequently became the majority shareholder, with ownership reported at 56.63% in the reference material. This international activity made Aier more than a domestic hospital chain, although China remains its principal operating market. Operationally, Aier uses a multi-tier hospital structure designed to connect different levels of specialist capacity. The model includes Tier IV facilities at the lowest level and Tier I facilities at the highest level, with higher-tier hospitals serving as referral, training and complex-care centers. The group’s flagship hospital is located in Shanghai. Its business scope is therefore broader than a single hospital brand: it combines local patient-facing hospitals, higher-level specialist institutions, professional education, optometry and overseas healthcare assets. Aier has also attracted public scrutiny over patient-safety and clinical-conduct incidents. A 2021 dispute involving physician and public-health figure Ai Fen concerned cataract surgery performed in 2020 and a later retinal-detachment complaint. In 2023, video footage from a Guigang hospital showing a surgeon handling an elderly patient roughly during surgery led to a public response from Aier. The group apologized, said the incident had not been reported promptly to headquarters, dismissed the hospital’s chief executive and suspended the surgeon. These events are part of the brand’s public record and underscore the governance and quality-control challenges associated with operating a large, decentralized healthcare network.

Aier Eye Hospital was founded in 2003 by Chen Bang, who had previously established businesses in the medical sector. The first Aier hospital opened in Changsha, Hunan, where the group remains headquartered. From the beginning, the organization pursued a specialist rather than general-hospital model, concentrating on ophthalmology and building a repeatable chain format. A significant early financing event occurred in 2006, when the International Finance Corporation provided a CNY 64 million loan. The financing supported expansion and was intended to help increase access to higher-quality eye care. In 2009, the company associated with the Aier hospital network completed an initial public offering on the Shenzhen Stock Exchange under ticker 300015.SZ. The listing provided a public-market funding base and was described as the first listing of a medical institution in China. The group subsequently developed an education and training platform. In 2013, it established the Aier School of Ophthalmology at Central South University and a College of Optometry with Hubei University of Science and Technology. The initiatives connected the hospital network with formal ophthalmic and optometric education and helped broaden the group’s professional infrastructure. Aier’s geographic growth included both acquisitions and minority investments. In 2015, it acquired Hong Kong Asia Medical Group, marking expansion into Hong Kong. In 2017, it acquired Clinica Baviera, a Spanish eye-clinic company described in the reference material as Europe’s largest, and acquired an eye clinic in the United States. In December 2019, Aier acquired a 35% stake in Singaporean company SEC Healthcare and later increased its ownership to 56.63%, making it the majority shareholder. The group’s hospital system is organized through multiple tiers, with Tier IV at the lowest level and Tier I at the highest. This structure is intended to distribute routine services across local hospitals while directing more complex cases, specialist expertise and training toward higher-level institutions. Aier’s flagship hospital is in Shanghai. The overall model combines clinical services, referral relationships, optometry, education and overseas operations. Capital raising remained part of the group’s development strategy. In September 2022, Aier secured CNY 3.5 billion in a private placement led by ICBC Credit Suisse Asset Management. The stated purposes were to increase patient capacity and provide working capital. No current financial performance figures are included here because the available reference material does not provide a sufficiently specific reporting period and source citation. Aier has faced controversies concerning clinical outcomes and patient treatment. In 2021, Ai Fen disputed the outcome of cataract surgery performed at Aier in May 2020, reporting that her retina later detached and that she was nearly blind in one eye. In December 2023, a video posted on Chinese social media showed a surgeon at the Guigang hospital apparently striking or roughly handling an elderly patient during surgery. Aier said local anesthesia had caused patient intolerance and that a language barrier complicated communication, but apologized for the conduct. The patient reportedly suffered forehead bruising; her son also said she later became blind in the left eye, although the available material does not establish that the blindness resulted from the incident. Aier said the event had occurred in December 2019 and had not been escalated to headquarters. It dismissed the hospital’s chief executive and suspended the surgeon. These episodes illustrate the quality-control, reporting and governance issues that can accompany a large multi-site healthcare network.

1. 2022CNY 3.5 billion private placement

   Aier raised CNY 3.5 billion in a private placement intended to increase patient capacity and supplement working capital.

   Source
2. 2019Majority investment in SEC Healthcare

   Aier acquired an initial 35% stake in Singapore’s SEC Healthcare and later increased its ownership to 56.63%.

   Source
3. 2017Expansion into Spain and the United States

   Aier acquired Clinica Baviera in Spain and an eye clinic in the United States.

   Source
4. 2015Hong Kong expansion

   Aier acquired Hong Kong Asia Medical Group.

   Source
5. 2013Ophthalmology and optometry schools established

   Aier established the Aier School of Ophthalmology at Central South University and a College of Optometry with Hubei University of Science and Technology.

   Source
6. 2009Public listing in Shenzhen

   The related company completed an IPO and began trading on the Shenzhen Stock Exchange under ticker 300015.SZ.

   Source
7. 2006International Finance Corporation provides expansion financing

   The IFC provided a CNY 64 million loan to support expansion and access to eye care.

   Source
8. 2003Aier is founded and opens its first hospital

   Chen Bang founded Aier and opened the first Aier hospital in Changsha, Hunan.

   Source

A chain-based, specialist ophthalmology healthcare provider combining local hospitals, referral centers, professional education and international eye-care assets.

• Ophthalmology specialist healthcare servicesMedical services2003

  The core offering is delivered through specialist eye hospitals and a multi-tier network. Services include examinations, diagnosis, medical treatment, surgery, postoperative care and follow-up for a broad range of ophthalmic conditions. The exact service mix varies by hospital tier, location and clinical capability.

• Cataract careOphthalmology services

  Cataract services include assessment, diagnosis, surgical treatment and postoperative management. They are a major component of Aier’s clinical activity and are provided through its hospital network, subject to patient assessment and the capabilities of the individual facility.

• Glaucoma careOphthalmology services

  Glaucoma care covers examination, diagnosis, treatment and continuing clinical monitoring. Treatment pathways depend on the patient’s condition and may differ between local hospitals and higher-tier referral institutions.

• Myopia and refractive surgeryVision correction

  Aier provides myopia-related procedures and refractive vision-correction services for appropriately assessed patients. The available technique and suitability are determined through professional ophthalmic examination rather than by the brand alone.

• Optometry and vision-care servicesOptometry2013

  The group’s broader eye-care offering includes optometry-related services and vision assessment. Its education investments in optometry support this part of the operating model, while individual clinical services vary across markets and facilities.

• 2022Raise capital for capacity and working capitalOther

  Aier pursued additional funding to support patient-capacity expansion and operating needs.

  What changed. The company completed a CNY 3.5 billion private placement led by ICBC Credit Suisse Asset Management.

  Aftermath. The proceeds were designated for increasing patient capacity and supplementing working capital. The reference material reported a 3% share-price increase following the financing.

  Private-placement proceeds. CNY 3.5 billion (September 2022)

  Source
• 2019Increase investment in SEC HealthcareM&A

  Aier sought to expand its international ophthalmology platform through Singapore-based SEC Healthcare.

  What changed. After acquiring an initial 35% stake, Aier increased ownership to 56.63%, becoming the majority shareholder.

  Aftermath. The investment expanded Aier’s presence in Singapore and added an overseas healthcare asset to its network.

  Source

• 2023Guigang patient-treatment incidentControversy

  A video circulated showing a surgeon apparently striking or roughly handling an 82-year-old patient during surgery at an Aier hospital in Guigang. Aier apologized, said the event had taken place in 2019 and had not been reported to headquarters, and announced the dismissal of the hospital chief executive and suspension of the surgeon.

  Source
• 2021Ai Fen cataract-surgery disputeControversy

  Ai Fen publicly disputed the outcome of cataract surgery performed by Aier in May 2020. Five months after the procedure, she reported near blindness in one eye and retinal detachment, resulting in a malpractice-related dispute.

  Source

• 2022Aier raises capital through private placement

  Aier secured CNY 3.5 billion through a private placement led by ICBC Credit Suisse Asset Management. The stated uses were expanding patient capacity and supplementing working capital.

  Other
  Source
• 2017Aier expands through overseas acquisitions

  The group acquired Clinica Baviera in Spain and an eye clinic in the United States, extending its international operating footprint.

  M&A
  Source
• 2017Aier expands its international ophthalmology platform through Clínica Baviera

  Aier acquired a controlling interest in Spanish ophthalmology company Clínica Baviera, marking a significant step in the group’s international expansion.

  M&A
  Source
• 2013Aier establishes ophthalmology and optometry education institutions

  Aier established an ophthalmology school at Central South University and a College of Optometry with Hubei University of Science and Technology.

  Other
  Source
• 2009Aier completes Shenzhen Stock Exchange IPO

  The related company became publicly listed on the Shenzhen Stock Exchange under ticker 300015.SZ.

  Other
  Source
• 2009Aier Eye Hospital Group lists on the Shenzhen Stock Exchange

  Aier Eye Hospital Group became a publicly traded company in China under stock code 300015, supporting its subsequent expansion of hospitals, equipment and clinical capabilities.

  Other
  Source
• 2006International Finance Corporation provides expansion loan

  The International Finance Corporation provided Aier with a CNY 64 million loan to support expansion and broader access to eye care.

  Other
  Source
• Aier continues expansion of its hospital and clinic network

  The group has continued to develop and operate ophthalmology facilities across Chinese provinces and cities, using a network model that combines regional hospitals, specialist centers and referral capabilities.

  Other
  Source

1. Aier Eye Hospital
2. Aier Eye Hospital official website
3. Aier expands its international ophthalmology platform through Clínica Baviera
4. Aier Eye Hospital Group lists on the Shenzhen Stock Exchange
5. Aier continues expansion of its hospital and clinic network